SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021)

SAB Biotherapeutics (SABS) posted Preferred Stock Liabilities of $116.2 million for Q3 2021, up 13.66% on a QoQ basis from $102.2 million in Q2 2021.

SAB Biotherapeutics (SABS) Preferred Stock Liabilities (2021) Analysis & Trends

SAB Biotherapeutics' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $116.2 million for Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Stock Liabilities (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	SAB Biotherapeutics	170.64 Mn	170.64 Mn	-	-

Download Data